RVM-V001 / RVAC Medicines - LARVOL DELTA

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals (clinicaltrials.gov) - P1b | N=24 | Terminated | Sponsor: RVAC Medicines (US), Inc. | N=48 ➔ 24 | Trial completion date: Feb 2024 ➔ Sep 2023 | Active, not recruiting ➔ Terminated; Changes in COVID-19 pandemic landscape

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 (clinicaltrials.gov) - P1 | N=13 | Terminated | Sponsor: RVAC Medicines (US), Inc. | N=54 ➔ 13 | Trial completion date: Sep 2023 ➔ Jun 2023 | Recruiting ➔ Terminated; The landscape of the study area changed, making it impossible to continue the study.

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals (clinicaltrials.gov) - P1b | N=48 | Active, not recruiting | Sponsor: RVAC Medicines (US), Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals (clinicaltrials.gov) - P1b | N=48 | Recruiting | Sponsor: RVAC Medicines (US), Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: RVAC Medicines (US), Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: RVAC Medicines (US), Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease